This real-time learning process was carried out in order to identify the gaps and needs within World Vision’s current Ebola Virus Disease (EVD) response in Sierra Leone and to inform World Vision on how other surrounding countries (specifically those with national offices such as Mali, Ghana, Nig...er, Mauritania, Senegal and Chad) should prepare for a possible Ebola outbreak.
more
mBio, Vol. 6 Issue 2, March/April 2015
Available evidence demonstrates that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission, but this is based on a limited number of studies. In this review, the authors address what we know and what ...we do not know about Ebola virus transmission. They also hypothesize that Ebola viruses have the potential to be respiratory pathogens with primary respiratory spread.
more
This study examines the gendered impacts of the Ebola virus disease (EVD) in Liberia in the largest outbreak of EVD ever recorded. The findings are based on an extensive two-week desk study and one-week participatory field study conducted in January 2015 in the cities of Monrovia and Buchanan in Lib...eria
more
A quick reference guide for health authorities and health-care workers
Revised 2015
Almost 30 countries vulnerable to a new Ebola-style Epidemic, jeopardising the future of millions of Children. The report ranks the world’s poorest countries on the state of their public health systems, finding that 28 have weaker defences in place than Liberia where, alongside Sierra Leone and Gu...inea, the current Ebola crisis has already claimed 9,000 lives, and provoked an extraordinary international response to help contain it.
more
Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD011386. DOI: 10.1002/14651858.CD011386.pub2
Free access from the website http://onlinelibrary.wiley.com/enhanced/doi/10.1002/14651858.CD011386.pub2
Watch a short film which accompanies this Cochrane Review and talks about applying ...the findings in relevant clinical settings at http://www.cochrane.org/news/new-evidence-helps-health-workers-fight-against-ebola
more
The report will describe how the Ebola Response MPTF, which has attracted contributions from 38 Member States, one business and many individuals, has offered a transparent and strategic tool to support the Ebola response. As of 31 January 2015, the Fund had total pledges amounting to US$142 million,... out of which US$132 million have been deposited
more
Summary of research into the consequences of the Ebola outbreak for children and communities in Liberia and Sierra Leone
This study describes the range of impacts that Ebola has had on children and families in Liberia and Sierra Leone, looking beyond the immediate health effects
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o...f their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all the unwanted effects of medications are mentioned.
more
This guide is intended for shelter operators, planners, and staff, as well as emergency managers, public health professionals, and radiation protection professionals who participate in shelter planning and could be called upon to support shelter operations. This guide provides information on the inc...ident-specific considerations that shelter operators will
need to take into account in a radiation emergency. Shelter operations include other mass care and emergency assistance activities that are required to support a sheltered population, such as feeding, providing essential supplies, and assisting with reunification of family and friends. Guidance to support such activities can be found in other planning resources. The information in this guide is intended to complement, not supplant, existing shelter protocols and responsibilities.
more
The International Pharmaceutical Federation (FIP) is a global federation of national associations of pharmacists and
pharmaceutical scientists. In order to support these associations in their fight against AMR, FIP has prepared this
briefing document. It is an overview of the different activities ...that community and hospital pharmacists are involved
into prevent AMR and to reverse AMR rates.
more
AMR is a serious and growing global problem. A WHO report released in 2014 stated that this serious threat is no longer a prediction for the future it is happening now in every region of the world and has potential to affect anyone, of any age in any community – a real threat to the public health.... The coming together of the various important stakeholders to develop this document is the testimony of their agreement of how serious is the issue at hand and their intentions to combat AMR is translated into an Action Plan. WHO also reported that there are about 2 million people in the US are infected with the AMR organism while 23,000 die annually from AMR infections. Fiji is just 10 hours journey away from the United States of America therefore Fiji must act now to keep our population safe from AMR organisms.
more
Policy
June 2015
Training Menus, Facilitation Tips, and Participatory Training Modules
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more